Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25956024 | 1.00 | NQO1 (0.56) | NQO1MAPTALDH1A1CYP1A2KDM4E | |
| SCHEMBL3035998 | 0.92 | NQO1 (0.67) | NQO1MAPTALDH1A1CYP1A2NPC1 | |
| SCHEMBL13382488 | 0.87 | LTA4H (0.46) | NQO1MAPTALDH1A1CYP1A2KDM4E | |
| SCHEMBL13209791 | 0.86 | NQO1 (0.58) | NQO1MAPTALDH1A1CYP1A2NPC1 | |
| SCHEMBL83852 | 0.85 | CA1 (0.61) | MAPTALDH1A1CYP1A2KDM4ENPC1 | |
| SCHEMBL10112753 | 0.85 | CA1 (0.61) | MAPTALDH1A1CYP1A2KDM4ENPC1 | |
| 1-Methoxy-4-Ethoxybenzene SCHEMBL354674 | 0.85 | NQO1 (0.78) | NQO1MAPTALDH1A1CYP1A2KDM4E | |
| SCHEMBL25986528 | 0.85 | CA1 (0.61) | MAPTALDH1A1CYP1A2KDM4ENPC1 | |
| SCHEMBL23512941 | 0.85 | NQO1 (0.52) | NQO1MAPTALDH1A1CYP1A2KDM4E | |
| SCHEMBL18387603 | 0.85 | NQO1 (0.52) | NQO1MAPTALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129965-A1 | THERMOPLASTIC RESIN HAVING CARBONATE BOND | Mitsubishi Chemical Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-3236318-B1 | TONER FOR ELECTROPHOTOGRAPHY | KAO CORP (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-9856376-B2 | Aromatic polyamide films for solvent resistant flexible substrates | AKRON POLYMER SYSTEMS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150376364-A1 | HYDROPHILIC MEMBRANES AND METHOD OF PREPARATION THEREOF (IV) | CYTIVA US LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8969377-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8852841-B2 | Toner for electrostatic image development | KAO CORPORATION (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8309291-B2 | Polyester for toner | KAO CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8211827-B2 | Dye receptor layer compositions | KAO CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8187779-B2 | Toner for electrostatic image development | KAO CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20110253434-A1 | EPOXY RESIN COMPOSITION, AND PREPREG AND PRINTED CIRCUIT BOARD USING THE SAME | TAIWAN UNION TECHNOLOGY CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| US-7691477-B2 | Polyformals as a coextrusion protective layer on polycarbonate | BAYER MATERIALSCIENCE AG (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20090143526-A1 | COATING COMPOSITION AND COATED ARTICLE | KANSAI PAINT CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7208564-B2 | Branched polyformals and copolyformals their preparation and use | BAYER MATERIALSCIENCE AG (DE) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | SLC9A1, SLC9A2, SLC10A2 | NQO1 2318/4885MAPT 4590/4885ALDH1A1 3416/4885 |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC9A1, SLC9A2 | NQO1 2093/4885MAPT 4756/4885ALDH1A1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.